Andy Scharenberg, MD

Andy Scharenberg is Scientific Co-founder of GentiBio and Chair of its Scientific Advisory Board In addition, Andy is Co-founder and CEO of Umoja Biopharma, an MPM Capital portfolio company, and an executive partner at MPM Capital. He is recently retired from prior positions as Attending Physician at Seattle Children’s Hospital and Professor of Pediatrics and Adjunct Professor of Immunology at the University of Washington School of Medicine in Seattle. Prior to founding Umoja, Andy co-directed the Program in Cell and Gene Therapy at Seattle Children’s Research Institute, working to translate cell and gene therapies for the treatment of inherited immunologic and blood diseases. Immeditaley prior to Umoja, he was chief scientific officer (CSO) of Casebia Therapeutics. Previously, he was the CSO  of Cellectis Therapeutics, where he initiated the development of an allogeneic CAR T cell platform that is the foundational technology for Allogene, and co-founded Pregenen Inc., a gene editing and cell-signaling technology company that was acquired by bluebird bio in 2014. Andrew earned his M.D. from the University of North Carolina School of Medicine. He completed his residency at the University of North Carolina Children’s Hospital and his fellowship in immunology at NIH and at the Division of Experimental Pathology, Beth Israel Hospital.